WELCOME to this Patient Advocacy organization's informational archive provided by MS Views and News

· Our live MS educational seminars average 72 people per educational program. SINCE our first program in February 2010, we have hosted more than 150 educational programs.

· Visit our Multiple Sclerosis Learning channel on YouTube archived by topic here: www.youtube.com/msviewsandnews

* Be Empowered with beneficial Multiple Sclerosis (MS) information - See our listings of upcoming Educational Programs --

Visit MS Views and News.org

joomla ecommerce template

View all the resources found on the left side of this blog. Use our 'search by topic' tool, when wanting to find specific information

.

==================================

Monday, November 5, 2012

New Multiple Sclerosis Drug Proves Effective Where Others Have Failed

ScienceDaily (Oct. 31, 2012) — Alemtuzumab, a drug previously used to treat a type of leukemia, shown to help people with early multiple sclerosis who relapsed on previous drugs as well as patients who had not yet been treated.


A drug which 'reboots' a person's immune system has been shown to be an effective treatment for multiple sclerosis (MS) patients who have already failed to respond to the first drug with which they were treated (a 'first-line' therapy), as well as affected individuals who were previously untreated. The results of these two phase III clinical trials were published November 1 in the journal TheLancet.
The new studies, sponsored by Genzyme (a Sanofi company) and Bayer Schering Pharma, showed that alemtuzumab significantly reduces the number of attacks (or relapses) experienced by people with MS compared to interferon beta-1a (known commercially as Rebif). This was seen both in patients who had not previously received any treatment (drug-naïve) and those who have continued to show disease activity whilst taking an existing treatment for MS.


Continue Reading
..


If you would like, you can comment to our blog posts
 LIKE this Blog by clicking the LIKE button - top left
 REMAIN up to date with MS News and Education
Visit: www.msviewsandnews.org  to register
.

No comments: